Increased risk of mycotic infections associated with sodium–glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: To determine the risk of mycotic infections associated with the use of sodium–glucose co‐transporter 2 inhibitors (SGLT2i) in a real‐world setting. Methods: We conducted a prescription sequence symmetry analysis using data from Truven Health MarketScan (2009–2015). We selected continuously enrolled patients newly initiating both an SGLT2i and an antifungal between 1 April 2013 and 31 December 2015 within time periods of 30, 60, 90, 180 or 365 days of each other. Adjusted sequence ratios (ASR) were calculated for each time period as the ratio of patients initiating SGLT2i first over those initiating an antifungal first adjusted for time trends in prescribing. Analyses were stratified by sex and type of SGLT2i. Results: There were 23 276 patients who newly initiated both SGLT2i and an antifungal in our study period. These patients were further classified into those initiating the two drugs within 365 (n = 17 504), 180 (n = 11 873), 90 (n = 7697), 60 (n = 5856) or 30 (n = 3650) days of each other. Increased risks of mycotic infections were present across all time periods, with the strongest effect observed in the 90‐day interval [ASR 1.53 (confidence interval, CI 1.43–1.60)]. Findings differed by sex [90‐day ASR females: 1.65 (CI 1.56–1.74); males 1.25 (CI 1.14–1.36)] and by SGLT2i [90‐day ASR canagliflozin 1.57 (CI 1.49–1.66); non‐canagliflozin 1.42 (CI 1.31–1.55)]. Conclusion: Initiation of SGLT2i was associated with an increased risk for mycotic infections. Findings from this commercially insured population in the real world are consistent with evidence available from clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Cited by
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
A safety update on sodium glucose co-transporter 2 inhibitors
Fitchett, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13611 · Cited by 99
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Lee, T., Kuo, S., Yang, C., & Ou, H. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14188 · Cited by 18
Self-citationLeBlanc, E. S., Brooks, N., Davies, M., & Chatterjee, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae655 · Cited by 11
Metadata
- Authors
- Adimadhyam, S., Schumock, G. T., Calip, G. S., Smith Marsh, D. E., Layden, B. T., & Lee, T. A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2018-11-08
- Volume
- 85
- Issue
- 1
- Pages
- 160-168
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2896296481
- Cited by
- 31
- References
- 3
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.